Strategic Performance Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Reported revenue faced significant year-over-year headwinds due to the divestiture of non-core assets to Companion Spine and the cessation of certain license revenue following reimbursement changes.
-
The integration of 17 new sales representatives from the Dilon distribution agreement consumed significant management resources, contributing to softer-than-expected Q2 sales performance.
-
Management attributed biologics underperformance to softness in legacy 'workhorse' product lines and ongoing headwinds in the amniotic membrane market tied to advanced wound care.
-
The launch of Trivium Shaped in May is driving early sales momentum by addressing surgeon needs for pre-shaped configurations that reduce preparation time and improve consistency.
-
The company is transitioning from a small commercial footprint to a scaled organization with over 25 reps and expanded national accounts teams to drive institutional adoption.
-
Strategic entry into the $1 billion hemostasis market via HEMOBLAST Bellows provides access to high-value hospital systems like Cleveland Clinic and Mass General.
Outlook and Strategic Assumptions
-
Full-year 2026 revenue guidance was modestly reduced to $99 million to $103 million, reflecting Q2 biologics softness and persistent amnio product headwinds.
-
Management expects accelerating biologics growth in Q3 and beyond as the newly integrated specialty reps move past the learning curve and begin selling the full product bag.
-
Substantially all HEMOBLAST Bellows sales are expected to transition to Xtant's own customer agreements, allowing for gross revenue recognition versus the net basis used in Q2.
-
The company anticipates significant sales synergies as legacy reps and new specialty reps share few overlapping call points, allowing for broader market penetration.
-
Future growth strategy relies on leveraging a broad regenerative medicine portfolio to become a 'one-stop shop' for hospital materials management and large practice groups.
Operational and Financial Context
-
A $5 million exclusivity fee paid to Dilon Technologies was recorded as a one-time operating expense in the second quarter.
-
Gross margin declined to 57.9% primarily due to the termination of Q-Code license revenue and reduced production efficiencies.
-
Revenue recognition for HEMOBLAST was approximately $600,000 to $700,000 lower than potential due to the timing of transitioning purchase orders from Dilon to Xtant.
-
Cash and cash equivalents decreased to $9.9 million as of June 30, 2026, compared to $17.3 million at the end of 2025.
Q&A Session Highlights
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Specific drivers of orthobiologics underperformance relative to initial expectations
-
Management identified 'old line' products like OsteoSelect and OsteoSponge as being down more than anticipated.
-
The Amnio product line remains soft, and while 'green shoots' were expected, the recovery has not yet materialized as planned.
Cross-selling opportunities and synergies from the Dilon sales force
-
The new reps provide entry into non-orthobiologic areas like OB/GYN where products like CollagenX and Amnio have strong applications.
-
The 17 new reps will be tasked with managing approximately 400 'transactional' independent agent accounts that previously lacked consistent coverage.
-
Management believes the new team's relationships with hospital materials management will facilitate larger institutional contracts.
HEMOBLAST revenue recognition and transactional volume expectations
-
Management maintains an expectation of over $1 million per month in gross transactional volume for HEMOBLAST.
-
A 'buffer' remains in Q3 guidance to account for any remaining orders that might still be processed through Dilon during the final stages of the contract transition.
